Patients with a history of ≥2 NOVs per night for ≥6 months (n=1333) were randomized to AV002 1.66mcg, AV002 0.83mcg, or placebo and treated for 12 weeks. FUSP and the percentage of nights with ≤1 NOV were measured. Safety evaluations included adverse events (AEs) and incidence of hyponatremia (moderate hyponatremia is defined as serum sodium 126-129 mmol/L and severe hyponatremia as ≤125 mmol/L).
By end of study, in both age groups the increase in FUSP (Table 1A)
and percentage of nights with ≤1 NOV (Table 1B)
from baseline were statistically significant compared to placebo in both treatment groups.
Incidence and severity of AEs in the AV002-treated groups were similar to placebo. The incidence of hyponatremia was low for both doses (Table 2).
Both ≥65y and ≥75y patients treated with AV002 demonstrated significant improvement in duration of first uninterrupted sleep period and percentage of nights with ≤1 nocturic void. For both age groups, the mean first uninterrupted sleep period after treatment was greater than 4 hours for 1.66mcg group and approximately 4 hours for 0.83mcg group. No patients treated with 0.83mcg (recommended starting dose for patients ≥65 years old) had severe hyponatremia. These results suggest AV002 is an effective therapy with a favorable safety profile in older adults with noctria due to nocturnal polyuria.
In conclusion, addressing nocturia in older adults may result in better quality of sleep, increased productivity during the day, and improved overall health and health-related quality of life.
Presented by: BRUCKER B M
Authors: KOBASHI K1, BRUCKER B M2, YANG A3, FRANCIS L3, NEWMAN D K4
Written by: Bilal Farhan, MD; Clinical Instructor, Female Pelvic Medicine and Reconstructive Surgery, University of California, Irvine Medical Center, Twitter: @Bilalfarhan79 at the 2018 ICS International Continence Society Meeting - August 28 - 31, 2018 – Philadelphia, PA USA